Asset profile
SP2086
Small molecule
Evidence outlook · registrational
Type 2 Diabetes: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. The registry's posted readout date (2014-01) has passed without a status update. Check News for topline announcements.
NCT01969357: The study randomly assigned 200 participants to SP2086, placebo, or sitagliptin and used quadruple blinding, with change in HbA1c as its primary clinical endpoint. However, no outcome results or statistical comparison are available, so the evidence supports only a moderate assessment rather than a stronger conclusion.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
79 competitors in this universe: 19 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 33 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SP2086: this drug | Phase 3 | Small molecule | DPP-4 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Linagliptin (Tradjenta) | Approved | Small molecule | DPP-4 | ||
| Saxagliptin (Onglyza) | Approved | Small molecule | DPP-4 | ||
| Sitagliptin (Januvia) | Approved | Small molecule | DPP-4 | ||
| Anagliptin (Suiny) | Phase 3 | Small molecule | DPP-4 | ||
| DBPR108 | Phase 3 | Small molecule | DPP-4 | ||
| Evogliptin (Suganon) | Phase 3 | Small molecule | DPP-4 | ||
| Gemigliptin (Zemiglo) | Phase 3 | Small molecule | DPP-4 | ||
| Gosogliptin | Phase 3 | Small molecule | DPP-4 | ||
| Henagliflozin | Phase 3 | Small molecule | Sodium-glucose cotransporter 2 (SGLT2), DPP-4 | ||
| MP-513 | Phase 3 | Small molecule | DPP-4 | ||
| Omarigliptin (Marizev) | Phase 3 | Small molecule | DPP-4 | ||
| SYR-472 | Phase 3 | Small molecule | DPP-4 | ||
| Teneligliptin (Tenelia) | Phase 3 | Small molecule | DPP-4 | ||
| Trelagliptin (Zafatek) | Phase 3 | Small molecule | DPP-4 |
…and 64 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
13 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.